[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.129.152. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
July 5, 2000

New System for Monitoring Intrapartum Fetal Oxygen Saturation

Author Affiliations
 

Not Available

Not Available

JAMA. 2000;284(1):33. doi:10.1001/jama.284.1.33-JFD00005-2-1

The FDA has approved OxiFirst Fetal Oxygen Saturation Monitoring System (Mallinckrodt/Nellcor, Pleasanton, Calif), the first pulse oximeter for continuous monitoring of intrapartum fetal oxygen saturation (FSpO2). Use of the OxiFirst system is indicated as an adjunct to fetal heart rate (FHR) monitoring in the presence of a nonreassuring fetal heart rate pattern and for a singleton fetus in vertex presentation with a gestational age of at least 36 weeks. The system consists of an intrauterine sensor, a connecting cable, and a patient monitor.

First Page Preview View Large
First page PDF preview
First page PDF preview
×